Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Unit 5. Dermatomyositis,Scleroderma – Etiology, Clinical features, Diagnosis and Treatment. 1.5 hr Subacute cutaneous lupus erythematosus Discoid lupus erythematosus - Etiology, Clinical features, Diagnosis and Treatment. 0.5 hr Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Connective Tissue Diseases(CTD) -concept • Autoimmune diseases– diseases associated with specific autoantibodies • Connective-tissue disorders— collagen-vascular disorders, are characterized by autoantibody-mediated connective-tissue abnormalities. • Histopathology: --Perivascular collagen deposition =Collagen Vascular Diseases • Symptoms nonspecific & overlapping Sir Run Run Shaw Hospital Prof. Cheng Connective Tissue Diseases(CTD) •Dermatomyositis •Scleroderma-Systemic Sclerosis-Diffuse Sclerosis* Localized Fibrosing Disorders - Linear Scleroderma Morphea, & Regional Fibrosis •Lupus Erythematosus (LE): Acute-, Subacute Cutaneous-LE, Discoid-LE, Drug-Induced -, Bullous -, Systemic -, Neonatal •Mixed Connective Tissue Disease, MCTD •Sjogren Syndrome •Eosinophilia-Myalgia Syndrome •Eosinophilic Fasciitis •CREST Syndrome Sir Run Run Shaw Hospital Prof. Cheng Dermatomyositis,DM 皮肌炎 Sir Run Run Shaw Hospital Prof. Cheng Definition of DM • an idiopathic inflammatory myopathy (IIM) with characteristic cutaneous changes • a systemic disorder that frequently affects the joints, esophagus, lungs, heart (rarely) • Related to Malignancy (>60y) • Calcinosis (in children, 40%) • Prognosis – Level of myopathy – y/n malignancy – Cardiopulmonary Involvment Sir Run Run Shaw Hospital Prof. Cheng Dermatomyositis -concept • Proximal muscle weakness nonsuppurative inflammation of skeletal muscle • 5 cases per million per year • 2:1 female:male • No racial disposition • Can occur at any age, 2 peaks – Adults – 50y(40-60) – Children – 5-15y Sir Run Run Shaw Hospital Prof. Cheng Cause & Pathophysiology of DM • Genetic – HLA DR3,DR5,DR7, TNF-a polymorphism • Immunologic abnormalities – antibody-mediated cell cytotoxicity vascular inflammation • Infectious – viral agents, Toxoplasma, Borrelia • Drug-induced – Hydrea, penicillamine, statin, quinidine, phenylbutazone • Silicone breast implants – anecdotal Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Clinical features of DM • eruptions on exposed surfaces-as one of the initial manifestations • Muscle involvement – manifests as proximal muscle weakness. • Systemic manifestations may occur --arthralgia, arthritis, dyspnea, dysphagia, arrhythmia, dysphonia Sir Run Run Shaw Hospital Prof. Cheng Clinical features of DM Hallmark Skin lesion • the characteristic – a heliotrope discoloration on the upper eyelids – Gottron papules: violaceous, scaly papule-macule – nailfold telangiectasia – poikiloderma in a photodistribution. – Pruritic – Scaly scalp or hair loss Classic Cutaneous Manifestations Sir Run Run Shaw Hospital Prof. Cheng The heliotrope flower The heliotrope rash is a characteristic and pathognomonic cutaneous feature of DM. Sir Run Run Shaw Hospital Prof. Cheng Systemic Manifestations/Associations of Dermatomyositis/Polymyositis •Musculoskeletal • Myositis with proximal weakness • Muscle atrophy and contracturea • Muscular calcificationa •Cardiac • Cardiomyopathy • Conduction defects •Respiratory • Dysphonia • Diffuse interstitial pneumonitis/fibrosis • Aspiration pneumonia • Respiratory failure from muscle weakness •Gastrointestinal • Proximal dysphasia • Large bowel infarction/perforation secondary to vasculopathya •Ophthalmologic • Retinopathya • Internal malignancyb Sir Run Run Shaw Hospital Prof. Cheng Lung disease — •Interstitial lung disease (ILD) is an important complication may be associated with rapidly progressive pulmonary failure and death •respiratory insufficiency may result from diaphragmatic and chest wall muscle weakness Sir Run Run Shaw Hospital Prof. Cheng Malignancy of DM •paraneoplastic processes ---linked to oncogenesis & autoimmunity •Including: Nasopharyngeal cancer breast cancer pancreatic cancer ovarian cancer cholangial cancer laryngeal cancer tongue cancer Lymphoma lung cancer colorectal cancer stomach cancer esophageal cancer liver cancer renal cancer Sir Run Run Shaw Hospital Prof. Cheng Complications •Cutaneous Ulceration •Systemic Vasculopathy •Calcinosis •Internal Malignancy •Opportunistic Infections and Lymphoma Sir Run Run Shaw Hospital Prof. Cheng Amyopathic DM (ADM) • • • • Typical cutaneous manifestations No muscle symptoms Normal muscle enzymes Subclinical muscle disease – Px – mild proximal weakness – EMG – mildly abnormal – Abnormal US, MRI, Biopsy • new autoantibodies (140 kDa, 155 kDa, and Se) might serve as serologic markers • may reflect an underlying malignancy ! Sir Run Run Shaw Hospital Prof. Cheng Laboratory Studies of DM • elevation of Muscle enzyme creatine kinase(CK)level,aldolase level test Aspartate aminotransferase(AST) lactate dehydrogenase (LDH)tests • serologic abnormalities: *ANA, * three major categories of myositis-specific Abs (MSAs): 1,Abs to aminoacyl-tRNA synthetases (antisynthetase Abs ) including anti-Jo-1; 2, Abs to signal recognition particle (anti-SRP Abs); 3,Abs to Mi-2, a nuclear helicase. * other myositis-specific autoantibodies Sir Run Run Shaw Hospital Prof. Cheng Autoantibodies in Idiopathic Inflammatory Dermatomyositis Autoantibody Median Molecular Prevalence Specificity Clinical Association High Specificity for DM/PM 155 kDa and/or Se 140 kDa Fer 20%–80% transcriptional Classic DM, clinically amyopathic DM with intermediary factor-1 increased risk of internal malignancy 53% helicase C domain protein Clinically amyopathic DM with increased 1 (IFIH1)/melanoma risk for interstitial lung disease differentiation-associated gene 5 (MDA-5) 20% Histidyl-tRNA synthetase PM, antisynthetase syndrome 15% Helicase nuclear proteins Shawl sign, cuticular overgrowth 5% Signal-recognition particle Fulminant DM/PM, cardiac involvement 3% Threonyl-tRNA Antisynthetase syndrome synthetase 3% Alanyl-tRNA synthetase Antisynthetase syndrome Rare Isoleucyl-tRNA Antisynthetase syndrome synthetase Rare Glycyl-tRNA synthetase Antisynthetase syndrome, possibly increased frequency of skin changes Rare Elongation factor 1 — Mas Rare Small RNA KJ Rare Translation factor — Sir Run Run Shaw Hospital Prof. Cheng Jo-1 Mi-2 SRP PL-7 PL-12 OJ EJ — Autoantibodies in Idiopathic Inflammatory Dermatomyositis Autoantibody Median Molecular Prevalence Specificity Low Specificity for DM/PM ANA 40% SsDNA 40% PM-Scl (PM-1) 40% Ro (52-kDa Ro) 15% U1RNP Ku 10% 3% U2RNP 1% Clinical Association Clinically amyopathic DM (80%) SLE, SSc Overlap with scleroderma Ribosomal RNA processing enzyme RNP Overlap with SSJ, SCLE, neonatal LE/CHB, SLE U1RNP Overlap connective tissue disease DNA end-binding Overlap with scleroderma repair protein complex U2RNP Overlap with scleroderma Sir Run Run Shaw Hospital Prof. Cheng Imaging Studies • • • • • MRI Chest radiography A barium swallow Ultrasonography Electromyography (EMG) • CT scanning Other tests •Pulmonary function studies •Electrocardiography (ECG) •skin biopsy •Muscle biopsy Sir Run Run Shaw Hospital Prof. Cheng Histologic Findings Skin biopsy an interface dermatitis Muscle biopsy perivascular and interfascicular lymphocytic inflammation Sir Run Run Shaw Hospital Prof. Cheng perivascular and perimysial inflammation, & Hospital perifascicular necrosis. Sir Run Run Shaw Prof. Cheng Diagnosis of DM • • • • Proximal muscle weakness Elevated serum creatinine kinase Myopathic changes on electromyography Muscle biopsy with evidence of lymphocytic inflammation • Rashs(Gottron’s sign, heliotrope rash) • Positive auto-antibody:ANA,Jo-1 Sir Run Run Shaw Hospital Prof. Cheng Differential Diagnoses CREST Syndrome Parapsoriasis Graft Versus Host Disease Pityriasis Rubra Pilaris Lichen Myxedematosus Polymorphous Light Eruption Lichen Planus Psoriasis, Plaque Lupus Erythematosus, Acute Rosacea Lupus Erythematosus, Discoid Sarcoidosis Lupus Erythematosus, Subacute Cutaneous Tinea Corporis Morphea Urticaria, Chronic Multicentric Reticulohistiocytosis Sir Run Run Shaw Hospital Prof. Cheng Treatment of DM – general • difficult • Bed rest - in severe myopathy • Physical therapy prevents curvatures in children, lasting joint damage (rare) • Elevate head after eating – prevent aspirations, may need NGT(nasogastric tube) • High protein diet Sir Run Run Shaw Hospital Prof. Cheng Treatment • photosensitive - sun avoidance and sun protective measures, sunscreens; Hydroxychloroquine, chloroquine • symptomatic patients:Steroids • non-responders: immunosuppressive agents methotrexate cyclosporine azathioprine tacrolimus fludarabine cyclophosphamide leflunomide chlorambucil mycophenolate mofetil • Anti-TNF agents (Infliximab) • Rituximab,anti-CD20 antibody specific in targeting the antibody-producing B cells • IVIG Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Scleroderma (Systemic Sclerosis) Sir Run Run Shaw Hospital Prof. Cheng Scleroderma-Background • Scleroderma is derived from the Greek words skleros (hard or indurated) and derma (skin) • Hippocrates first described this condition as thickened skin • 1752, Carlo Curzio offered the first detailed description of scleroderma in a patient with hard skin-- described as woodlike or containing a dry hide • 1836, Giovambattista Fantonetti applied the term scleroderma to a patient's condition--described as dark leather-like skin who exhibited a loss of range of joint motion due to skin tightening. • 1945, Robert H. Goetz first described the concept of scleroderma as a systemic disease-he introduced the term progressive systemic sclerosis(PSS) to emphasize the systemic & often progressive nature of the disease Sir Run Run Shaw Hospital Prof. Cheng Scleroderma definition • a chronic multisystem disorder characterized by : --the overproduction & accumulation of collagen: **excessive fibrosis of the skin --with skin thickening & induration **fibrosis & chronic inflammatory infiltration in organs --structural and functional abnormalities of blood vessels & organs --GI tract, lung, heart and kidneys **immune system activation (autoimmunity) ** vasculopathy. Sir Run Run Shaw Hospital Prof. Cheng Etiology • Environmental factors 1) silica dust 2) organic solvents 3) biogenic amines 4) urea formaldehyde • Genetic predisposition • Defective immunoregulation 1) cell mediated immunity: CD4/CD8 , cytokines 2) humoral immunity 5) polyvinyl chloride – hypergammaglobulinemia 6) rapeseed oil – autoantibody production 7) bleomycin – antinuclear antibody (+) > 95% 8) L-tryptophan 9) silicone implant (?) Sir Run Run Shaw Hospital Prof. Cheng Pathogenesis Susceptible host Exogenous events Immune system activation Fibroblast activation Endothelial cell activation/damage End stage pathology Obliterative vasculopathy Fibrosis Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Pathogenesis • 1. Vasculopathy of small artery and capillary • • • • • • • • • • - endothelial cell injury - adhesion and activation of platelet - PG F, thromboxane A2 release - vasoconstriction & growth of endothelial cell and fibroblast - narrowing or obliteration, increased permeability 2. Fibrosis - aberrant regulation of fibroblast cell growth - increased production of extracellular matrix (collagen, fibronectin, and glycosaminoglycan) - thickening of the skin & fibrosis of internal organs Sir Run Run Shaw Hospital Prof. Cheng Classification 1. Systemic sclerosis (Scleroderma) – Diffuse cutaneous systemic sclerosis – Limited cutaneous systemic sclerosis – Overlap syndromes 2. Localized scleroderma -Morphoea -Linear scleroderma 3. Overlap syndromes – Features of systemic sclerosis together with those of at least one other autoimmune disease, e.g. SLE, RA, or polymyositis Sir Run Run Shaw Hospital Prof. Cheng Clinical features of Scleroderma Diffuse Limited Skin Involvement Distal and proximal Distal to elbows, face extremities, face, trunk Raynaud’s Phenomenon Onset within one year or at time of skin changes Organ Involvement Pulmonary (interstitial GI, pulmonary fibrosis); renal (renal hypertension crisis); gastrointestinal; cardiac Nail Fold Capillaries Dilation and dropout Dilation without significant dropout Antinuclear Antibodies Anti-topoisomerase Anti-centromere * CREST May precede skin disease by years syndrome - calcinosis, Raynaud's phenomenon, esophageal sclerodactyly, Sir Rundysmotility, Run Shaw Hospitaltelangiectasia Prof. Cheng Clinical features of Scleroderma 1. Vascular abnormalities Vasculopathy 1) Raynaud's phenomenon - cold hands and feet • reversible skin color change (white to blue to red) • - induced by cold temperature or emotional stress • - initial complaint in 3/4 of patients • - 90% in patients with skin change • (prevalence in the general population: 4-15%) 2) digital ischemic injury Sir Run Run Shaw Hospital Prof. Cheng Clinical features Scleroderma 2. Skin involvement (1) 1) stage-- - edematous phase - indurative phase - atrophic phase 2) firm, thickened bound to underlying soft tissue 3) decrease in range of motion loss of facial expression inability to open mouth fully contractures Sir Run Run Shaw Hospital Prof. Cheng Clinical features 2. Skin involvement (2) ulceration loss of soft tissue of finger tip pigmentation calcific deposit 3. Musculoskeletal system Polyarthritis and flexion contracture Muscle weakness and atrophy (primary /secondary) Sir Run Run Shaw Hospital Prof. Cheng Terminal digit resorption Acrolysis Sir Run Run Shaw Hospital Acrosclerosis Prof. Cheng Calcinosis Calcinosis & acrolysis Sir Run Run Shaw Hospital Prof. Cheng Clinical features 4. gastrointestinal involvement 1) esophagus: hypomotility and retrosternal pain, reflux esophagitis, stricture 2) stomach: delayed emptying 3) small intestine: pseudo-obstruction, paralytic ileus malabsorption, weight loss, cachexia 4)large intestine: chronic constipation fecal impaction diverticula Sir Run Run Shaw Hospital Prof. Cheng Clinical features 5. lungs 1) 2/3 of patients affected - leading cause of mortality and morbidity in later stage 2) pathology - interstitial fibrosis - intimal thickening of pulmonary arterioles (pulmonary hypertension) 3) Complains - dry cough breathlessness (Progressive dyspnea ) Sir Run Run Shaw Hospital Prof. Cheng Pulmonary fibrosis Sir Run Run Shaw Hospital Prof. Cheng Clinical features 6. kidney 1) pathology - intimal hyperplasia of the interlobular artery - fibrinoid necrosis of afferent arterioles - glomerulosclerosis 2) proteinuria, abnormal sediment, azotemia, microangiopathic hemolytic anemia, renal failure Sir Run Run Shaw Hospital Prof. Cheng Clinical features 7. Cardiovascular system • Pericarditis,pericardial effusion,myocardial fibrosis --Congestive heart failure --Dyspnea • conduction abnormalities --arrhythmia (irregular heart beats) --Palpitations --syncope 8.Exocrine glands – Xerostomia – xerophthalmia Sir Run Run Shaw Hospital Prof. Cheng Laboratory findings 1. ANA, RF 2. anti-Scl-70 (DNA topoisomerase I) antibody – 20-40% in diffuse scleroderma – 10-15% in limited scleroderma 3. anticentromere antibody – 50-90% in limited scleroderma – 5% in diffuse scleroderma Sir Run Run Shaw Hospital Prof. Cheng Scleroderma Autoantibodies 7 known scleroderma specific autoantibodies •Anticentromere Antibodies (ACA) •Anti-Scl-70 or anti-topoisomerase (TOPO) •Anti-U1-RNP (U1-RNP) or (antifibrillarin) •Anti-RNA Polymerase III (Pol 3) •Anti-U3-RNP (U3-RNP) •Anti-Th/To (Th/To) •Anti-Pm/Scl (Pm/Scl) Sir Run Run Shaw Hospital Prof. Cheng Clinical Association of Hallmark Autoantibodies in Systemic Sclerosis (SSc) Reactivity Target Antigen Frequency in HLA Association SSc (%) Centromere CENP proteins 20–30 HLA-DRB1 HLAspeckled pattern DQB1 Scl-70 Topoisomerase-1 15–20 speckled pattern RNAP III RNA polymerase 20 III speckled pattern nRNP U1-RNP speckled pattern Polymyositis/Scl nuclear staining pattern U3-RNP nuclear staining pattern 7–2RNP nuclear staining pattern PM-Scl Fibrillarin Th/To 15 3 4 2–5 Clinical Association Limited skin sclerosis, severe gut disease, isolated PAH, calcinosis HLA-DRB1 HLADiffuse skin sclerosis, DQB1 HLA-DPB1 pulmonary fibrosis and secondary PAH, increased SSc-related mortality rate HLA-DQB1 Diffuse skin sclerosis, hypertensive renal crisis, correlated with a higher mortality rate HLA-DR2, -DR4 Overlap features of SLE, HLA-DQw5, -DQw8 arthritis HLA-DQA1 HLALimited skin sclerosis, DRB1 myositis–sclerosis overlap, calcinosis HLA-DQB1 Diffuse skin sclerosis, myositis, PAH, renal disease HLA-DRB1 Limited skin sclerosis, Sir Run Run Shaw Hospital Prof. Cheng pulmonary fibrosis Imaging Studies • • • • • Chest radiography Echocardiography Ultrasonography CT scanning Esophagraphy Other tests •Pulmonary function test •Serum NT-proBNP •ECG Sir Run Run Shaw Hospital Prof. Cheng Scleroderma Diagnostic Criteria • One major criterion: scleromatous skin changes proximal to the metacarpal-phalangeal joints(近端掌骨,指骨关节) • Two of three minor criteria: sclerodactyly, digital pitting scars, or loss of substance from the finger pads bi-basilar pulmonary fibrosis on CXR * one major or 2 or more minor criteria Sir Run Run Shaw Hospital Prof. Cheng Recommended Diagnostic Procedures in SSc Organ Clinical Feature Involvement Vascular Raynaud system phenomenon Skin Scleroderma Calcinosis cutis Musculoskel Arthralgia/Synovitis etal system Muscle weakness Diagnostic Procedures •Coldness provocation •Nail fold capillaroscopy •Antinuclear antibody levels •Clinical assessment regarding puffy fingers, telangiectasias, mechanic hands, hypo/hyperpigmentations, digital ulcerations, dermatogenous contractures •Modified Rodnan skin score •20-MHz ultrasound •Radiography (X-ray, MRI, CT) •Clinical assessment regarding fist closuredeficiency, joint contractures, tendon friction rub, muscle weakness •Laboratory parameters: erythrocyte sedimentation rate, rheumatoid factor, antinuclear autoantibodies •Creatine kinase (>threefold?) •MRI, electromyography •Muscle Sir Runbiopsy Run Shaw Hospital Prof. Cheng Recommended Diagnostic Procedures in SSc Organ Involvement Clinical Feature Diagnostic Procedures Gastrointestinal Reflux Dysphagia •Gastro-/Esophageal-endoscopy tract Diarrhoea, obstipation •Oesophageal-szintigraphy •Oesophagus-manometry •Coloscopy Respiratory Dyspnoea •Lung function test (TLCOc SB, TLC, FVC) system •Radiography (X-ray or HR-CT) •Bronchioalveolar Lavage (BAL) (optional) Cardiac system Dyspnoea, arrhythmia •Electrocardiography (conduction blocks?) •Echocardiography (mPAP, diastolic dysfunction?, ventricular ejection fraction) •(Spiro-)Ergometry •24-hour blood pressure controls •Right-heart catheterization Kidney Renal function failure •Regular blood pressure controls (>140/90 mm Hg) •Ultrasound •Serum levels of creatinine, urine-analyses Sir Run Run Shaw Hospital Prof. Cheng (protein-, albuminuria, microelectrophoresis) Treatment • thickening & indurative Skin • • • - D-penicillamine - methotrexate - immunosuppressive agent: cyclosporin, IFN-,mycophenolate mofetil, cyclophosphamide, photopheresis, allogeneic bone marrow transplantation • Symptomatic (organ-specific) treatment Sir Run Run Shaw Hospital Prof. Cheng Treatment • Raynaud’s phenomenon and ischemia 1) avoid cold exposure layers of warm, loose-fitting clothing 2) quit smoking 3) vasodilator therapy - calcium channel blocker (nifedipine), prazosin, ACE-I -dipyridamole, aspirin 4) thrombosis and vascular flow compromise, tissue plasminogen activator--heparin, and urokinase 5) finger / toe necrosis - intravenous prostaglandin (PGE1, PGI2) - Bosentan - amputation Sir Run Run Shaw Hospital Prof. Cheng Treatment • Gastrointestinal • 1) reflux esophagitis and dysphagia • - elevation of head of bed • - small frequent meal • - avoid lying down within 3-4 hours of eating • - abstaining from caffeine-containing beverages, • cigarette smoking • - H2 blocker, proton-pump inhibitor • 2) gastroparesis: promotility agent (metoclopramide) • 3) malabsorption syndrome: broad spectrum antibiotics Sir Run Run Shaw Hospital Prof. Cheng Treatment • Pulmonary 1) Interstitial fibrosis - corticosteroid - cyclophosphamide, azathioprine 2) pulmonary artery hypertension - calcium channel blocker - prostacyclin - transplantation • Renal renal crisis episodes are best prevented and treated with the aggressive use of ACE inhibitors (eg:captopril) at the earliest signs of hypertension - later: dialysis Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Prognosis of scleroderma • quite variable and difficult to predict • cumulative survival diffuse limited 5 yr 70% 90% 10 yr 50% 70% • major cause of death 1) renal involvement 2) cardiac involvement 3) pulmonary involvement (Pulmonary hypertension, pulmonary fibrosis ) Sir Run Run Shaw Hospital Prof. Cheng Cutaneous Lupus concept • Affects only the skin • 1 of 10 patients will go on to develop SLE • Symptoms – rashes, hair loss, cutaneous vasculitis, skin ulcers, photosensitivity • Treatmentssunscreen, steroid creams and gels, antimalarials, immunosuppressives Sir Run Run Shaw Hospital Prof. Cheng Cutaneous Lupus Etiology • Genetic predisposition – Most cases are sporadic but may cluster in families (5-12% of family members have SLE) – Lupus is polygenic (more that one gene responsible) • Hormones (estrogen) • Environmental factors – Infections, stress, sunlight • Medications Sir Run Run Shaw Hospital Prof. Cheng Subacute cutaneous lupus erythematosus (SCLE) synonyms Subacute Cutaneous Lupus Erythematosus SCLE, Lupus Erythematosus Chronicus Disseminatus Superficialis definition •Subset of LE •intermediate between DLE and SLE •characterized by papulosquamous discoid plaques or annular polycyclic lesions •Photosensitivity •arthritis being the most frequent feature •Renal involvement is rare and mild Sir Run Run Shaw Hospital Prof. Cheng Etiology of SCLE *occurs in genetically predisposed individualshuman leukocyte antigen B8 (HLA-B8), HLA-DR3, HLA-DRw52, and HLA-DQ1 *A strong association exists with anti-Ro (SS-A) Abs *be related to -ultraviolet (UV) light modulation of autoantigens epidermal cytokines, and adhesion molecules with resultant keratinocyte apoptosis *Several drugs may induce SCLE: hydrochlorothiazide calcium channel blockers angiotensin-converting enzyme inhibitors, terbinafine, and TNF antagonists. Sir Run Run Shaw Hospital Prof. Cheng Clinical features of ScLE **papular eruptions-annular erythema or psoriasiformmay show a photosensitive distribution worsening each spring and summer pruritus,or asymptomatic SCLE may wax and wane **50% joint involvement small joints (hands and wrists). Arthritis may occur but is unusual (<2%). **Systemic complain fatigue May have Sjögren syndrome may manifest symptoms of SLE An necessary assessment for symptoms of pleuritis, pericarditis, neurologic involvement, and renal impairment Sir Run Run Shaw Hospital Prof. Cheng Physical of SCLE • clinical types: Annular or polycyclic (ring-shaped) erythematous --may mimic erythema annulare centrifugum Papulosquamous (scaly bumps) --may mimic psoriasis or lichen planus Vasculitis (purple spots) Nodular (lumps) • photodistributed-occurring mainly around the neck, on the back and front of the trunk • heal without scarring Sir Run Run Shaw Hospital Prof. Cheng Laboratory tests of SCLE Serologic testing positive ANA Anti-Ro (SS-A) in a high proportion: Annular SCLE - 90% Papulosquamous SCLE - 80-85% SCLE with vasculitis, SS, or C2d deficiency - ≥ 95% Mothers of neonates with LE - ≥90% Drug-induced SCLE - 70-80 % Anti-La (SS-B) Abs may occur Anti-native DNA (ds-DNA or nDNA) Abs may occur Other laboratory tests Anemia, leukopenia, and/or thrombocytopenia may be present Elevated ESR, RF. Complement levels,UA Sir Run Run Shaw Hospital Prof. Cheng Other Tests- biopsy LBT--60% positive on lesional skin. lupus band test Histologic Findings (1)vacuolar alteration of the basal cell layer (2)an inflammatory perivascular,periappendiceal cell infiltrate (usually lymphocytic), or in a subepidermal location (3)Epidermal atrophy, common, (4)follicular plugging is less frequent than inDLE. (5) An abundance of mucin often is seen within the dermis. Sir Run Run Shaw Hospital Prof. Cheng DDx of SCLE Dermatomyositis Lupus Erythematosus, Acute Erythema Annulare Centrifugum Lupus Erythematosus, Discoid Erythema Gyratum Repens Polymorphous Light Eruption Erythema Multiforme Psoriasis, Plaque Granuloma Annulare Sarcoidosis Henoch-Schönlein Purpura (Anaphylactoid Purpura) Tinea Corporis Hypersensitivity Vasculitis (Leukocytoclastic Vasculitis) Lichen Planus Sir Run Run Shaw Hospital Prof. Cheng Treatment of SCLE sun-protective measures: sunscreens, protective clothing, behavior alteration. Standard therapy: includes corticosteroids (topical, intralesional) and antimalarials(Hydroxychloroquine Chloroquine) Additional therapies: may be considered in selected patients include auranofin, dapsone, thalidomide, retinoids, interferon, and immunosuppressive agents. Sir Run Run Shaw Hospital Prof. Cheng Discoid lupus erythematosus (DLE) synonyms Discoid Lupus Erythematosus (DLE), Lupus Erythematosus Chronicus Discoides definition & Background •Benign subtype of LE •characterized by various-sized, well-defined, erythematous, scaly patches, with atrophy, scarring and pigmentation •Serologic abnormalities are uncommon Sir Run Run Shaw Hospital Prof. Cheng Causes & Pathophysiology of DLE •genetic predispositionUV light exposure Toll-like receptors are possibly involved in •heat shock protein -is induced in the keratinocyte following UV exposure or stress may act as a target for gamma (delta) T-cell–mediated epidermal cell cytotoxicity Sir Run Run Shaw Hospital Prof. Cheng Clinical features of DLE •a chronic, scarring, atrophic, photosensitive dermatosis • most are asymptomatic— mild pruritus or occasional pain Arthralgia or arthritis may occur •may manifest any symptom of SLE •5% or less patients accompanying systemic involvement-an assessment for symptoms of pleuritis, pericarditis, neurologic involvement, and renal involvement. Sir Run Run Shaw Hospital Prof. Cheng Physical of DLE •primary lesion – erythematous papule or plaque with slight-to-moderate scaling unsightly red scaly patchesleave postinflammatory pigmentation and white scars may be localised or widespread predominantly affects the cheeks, nose and ears, upper back, V of neck, backs of hands •Hypertrophic LE – thickened and warty skin resembling warts or skin cancers •Rarely, palmoplantar LE •hair follicles involvement-- scarring alopecia •may affect lips & mouth--causing ulcers & scaling. Sir Run Run Shaw Hospital Prof. Cheng DDx Actinic Keratosis Psoriasis, Plaque Dermatomyositis Rosacea Granuloma Annulare Sarcoidosis Granuloma Faciale Squamous Cell Carcinoma Keratoacanthoma Syphilis Lichen Planus Warts, Nongenital Lupus Erythematosus, Subacute Cutaneous Sir Run Run Shaw Hospital Prof. Cheng Comparison of the Major Types of LE-Specific Skin Disease Disease Features ACLE SCLE Classic DLE 0 0 + 0 + 0 0 ++ 0 ++ +++ +++ +++ +++ +++ 0 + 0 + ++ + +++ +++ +++ ++ ++ +++ ++ + ++ +++ 0 + + ++ +++ +++ 0 + Clinical features of skin lesions Induration Dermal atrophy Pigment changes Follicular plugging Hyperkeratosis Histopathology Thickened basement membrane Lichenoid infiltrate Periappendageal inflammation Lupus band Lesional Nonlesional Antinuclear antibodies Ro/SS-A antibodies By immunodiffusion By ELISA Antidouble-stranded DNA antibodies Hypocomplementemia Risk for developing SLE Sir Run +++ + 0 +++ + + +++ Shaw ++ Run Hospital+ Prof. Cheng Laboratory tests of DLE Serologic testing: 20% manifest positive ANA. Anti-Ro (SS-A): approximately 1-3% Antinative DNA (ds- or n-DNA) or anti-Sm Ab <5% Elevated ESR in some patients. RF may be positive. Complement levels may be depressed Sir Run Run Shaw Hospital Prof. Cheng Other Tests •Immunopathology findings (LBT): ca 90% lesional skin manifest a positive DIF-Deposition of Ig &/or complement at dermalepidermal junction --is a characteristic feature of LE • Mucin deposition •Urinalysis •Cytopenias may be present Sir Run Run Shaw Hospital Prof. Cheng Sir Run Run Shaw Hospital Prof. Cheng Treatment of DLE sun-protective measures Cosmetic measures Standard medical therapy: corticosteroids (topical or intralesional) antimalarials— Hydroxychloroquine chloroquine phosphate) Alternative therapies: auranofin dapsone, thalidomide,oral,topical retinoids, immunosuppressive agents— methotrexate (MTX), azathioprine, mycophenolate mofetil, lenalidomide phenytoin, interferon, acitretin, & chimeric monoclonal antibody. systemic corticosteroids are rarely effective Sir Run Run Shaw Hospital Prof. Cheng Thanks & questions? Sir Run Run Shaw Hospital Prof. Cheng